



uniQure to Participate in Multiple Conferences in February

February 1, 2018

LEXINGTON, Mass. and AMSTERDAM, the Netherlands, Feb. 01, 2018 (GLOBE NEWSWIRE) -- uniQure N.V. (NASDAQ:QURE), a leader in human gene therapy, today announced that members of company management or principal investigators will participate in upcoming business, medical and investor conferences during February.

- **Bentley University Innovator's Business Series, February 6, 2018 at Bentley University in Waltham, Massachusetts.**

- o Matthew Kapusta, chief executive officer of uniQure, will be the keynote speaker for a presentation entitled, "Delivering on the Promise of Gene Therapy" on Tuesday, February 6, 2018 at 5:00 p.m. EST.

- **SunTrust 4th Annual Orphan Drug Day, February 13, 2018 at the JW Marriott Essex House in New York City**

- o Company management will be hosting meetings with institutional investors throughout the day.

- **Leerink Partners 7th Annual Global Healthcare Conference, February 14 - 15, 2018 at the Lotte New York Palace Hotel in New York City**

- o Mr. Kapusta will be participating in a Fireside Chat on Wednesday February 14, at 9:00 a.m. EST. The live webcast can be accessed by the link displayed in the Investor section of the [uniQure](http://uniQure.com) website. The webcast replay will be available for at least 72 hours following the live event.

- **13th Annual Huntington's Disease Therapeutics Conference, February 26 - March 1, 2018 at the Parker Hotel in Palm Springs, California**

- o Investigators at the Centre for Molecular Medicine and Therapeutics & BC Children's Hospital Research Institute, University of British Columbia, Vancouver, Canada, will present novel, preclinical data on uniQure's proprietary investigational gene therapy, AMT-130, in humanized mice models of Huntington's disease. The presentation is expected to include data demonstrating non-selective silencing of mutant HTT and improvements in select behavioral and neuropathological Huntington's disease phenotypes.

About uniQure

uniQure is delivering on the promise of gene therapy - single treatments with potentially curative results. We are leveraging our modular and validated technology platform to rapidly advance a pipeline of proprietary and partnered gene therapies to treat patients with hemophilia, Huntington's disease and cardiovascular diseases.

uniQure Contacts

For Investors:

Maria E. Cantor

Direct: 339-970-7536

Mobile: 617-680-9452

m.cantor@uniQure.com

Eva M. Mulder

Direct: +31 20 240 6103

Mobile: +31 6 52 33 15 79

e.mulder@uniQure.com

For Media:

Tom Malone

Direct: 339-970-7558

Mobile: 339-223-8541

t.malone@uniQure.com